Elevate your local knowledge
Sign up for the iNFOnews newsletter today!

NEW YORK, N.Y. – The drugmaker Pfizer says its first-quarter profit dropped 15 per cent due to cheaper generic competition that continues to reduce sales of its multiple medicines and the end of some partnerships with other drug makers.
The maker of Viagra says net income was $2.33 billion, or 36 cents per share, for the January-March period. That’s down from $2.75 billion, or 38 cents per share, a year earlier.
Excluding one-time charges, income was 57 cents per share. Analysts surveyed by FactSet expected 55 cents per share.
Revenue totalled $11.35 billion, down 9 per cent. Analysts expected $12.08 billion.
Pfizer, which recently has made three unsuccessful offers to acquire rival AstraZeneca Plc, confirmed its 2014 profit forecast for earnings per share of $2.20 to $2.30 and revenue of $49.2 billion to $52.3 billion.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.